Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761

Vascular endothelial growth factor (VEGF) and its receptors

NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483

VEGF receptor signalling ? in control of vascular function

Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081

Requirement of Vascular Integrin α v β 3 for Angiogenesis

Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625

Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262

VEGF-targeted therapy: mechanisms of anti-tumour activity

Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673

Clinical translation of angiogenesis inhibitors

Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517

N -Methylated Cyclic RGD Peptides as Highly Active and Selective α V β 3 Integrin Antagonists

Dechantsreiter, M. A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S. L., & Kessler, H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm970832g · Cited by 838

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

Brooks, P. C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 659

Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins

Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D., Hynes, R. O., & Hodivala-Dilke, K. M. (2002) · Nature Medicine · doi:10.1038/nm0102-27 · Cited by 613

Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.

Haubner, R., Wester, H. J., Weber, W., Mang, C., Ziegler, S. I., Goodman, S. L., Senekowitsch–Schmidtke, R., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 563

A reevaluation of integrins as regulators of angiogenesis

Hynes, R. O. (2002) · Nature Medicine · doi:10.1038/nm0902-918 · Cited by 548

Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments

Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C., & Dejana, E. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200602080 · Cited by 525

Integrins and cancer

Varner, J. A., & Cheresh, D. A. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80115-3 · Cited by 522

Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments

Caswell, P. T., Chan, M., Lindsay, A. J., McCaffrey, M. W., Boettiger, D., & Norman, J. C. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200804140 · Cited by 388

PDGF-regulated rab4-dependent recycling of αvβ3 integrin from early endosomes is necessary for cell adhesion and spreading

Roberts, M., Barry, S., Woods, A., van der Sluijs, P., & Norman, J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00442-0 · Cited by 348

In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts

Chen, X., Conti, P. S., & Moats, R. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1956 · Cited by 347

The fibronectin-binding integrins α5β1 and αvβ3 differentially modulate RhoA–GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis

Danen, E. H. J., Sonneveld, P., Brakebusch, C., Fässler, R., & Sonnenberg, A. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200205014 · Cited by 333

Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma

Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6514 · Cited by 290

Endocytic transport of integrins during cell migration and invasion

Caswell, P., & Norman, J. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.03.004 · Cited by 256

Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an αv Integrin Antagonist

MacDonald, T. J., Taga, T., Shimada, H., Tabrizi, P., Zlokovic, B. V., Cheresh, D. A., & Laug, W. E. (2001) · Neurosurgery · doi:10.1097/00006123-200101000-00026 · Cited by 240

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

Eskens, F. A. L. M., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Böttcher, S., Wynendaele, W., Drevs, J., Verweij, J., & van Oosterom, A. T. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00057-1 · Cited by 225

Regulators of Endocytosis Maintain Localized Receptor Tyrosine Kinase Signaling in Guided Migration

Jékely, G., Sung, H.-H., Luque, C. M., & Rørth, P. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.06.004 · Cited by 224

Cancer Biology and Hormesis: Human Tumor Cell Lines Commonly Display Hormetic (Biphasic) Dose Responses

Calabrese, E. J. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440591034502 · Cited by 213

αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro

Nisato, R. E., Tille, J.-C., Jonczyk, A., Goodman, S. L., & Pepper, M. S. (2003) · Angiogenesis · doi:10.1023/b:agen.0000011801.98187.f2 · Cited by 207

Integrin signaling is critical for pathological angiogenesis

Mahabeleshwar, G. H., Feng, W., Phillips, D. R., & Byzova, T. V. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060807 · Cited by 206

Integrins: Molecular targets in cancer therapy

Tucker, G. C. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0043-3 · Cited by 203

α v‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin

Taga, T., Suzuki, A., Gonzalez‐Gomez, I., Gilles, F. H., Stins, M., Shimada, H., Barsky, L., Weinberg, K. I., & Laug, W. E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10265 · Cited by 198

Intrinsic Tyrosine Kinase Activity is Required for Vascular Endothelial Growth Factor Receptor 2 Ubiquitination, Sorting and Degradation in Endothelial Cells

Ewan, L. C., Jopling, H. M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G. J., Walker, J. H., Zachary, I. C., & Ponnambalam, S. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00462.x · Cited by 183

VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment

Gampel, A., Moss, L., Jones, M. C., Brunton, V., Norman, J. C., & Mellor, H. (2006) · Blood · doi:10.1182/blood-2005-12-007484 · Cited by 181

In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.

Mitjans, F., Meyer, T., Fittschen, C., Goodman, S. L., Jonczyk, A., Marshall, J. F., Reyes, G., & Piulats, J. (2000) · PubMed · Cited by 171

Moving Membrane up to the Front of Migrating Cells

Bretscher, M. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81246-5 · Cited by 164

Integrins in angiogenesis: multitalented molecules in a balancing act

Hodivala‐Dilke, K., Reynolds, A. R., & Reynolds, L. E. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0774-5 · Cited by 161

Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice

Reynolds, A. R., Reynolds, L. E., Nagel, T., Lively, J. C., Robinson, S. D., Hicklin, D. J., Bodary, S. C., & Hodivala‐Dilke, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2760 · Cited by 157

αvβ3 integrin and angiogenesis: a moody integrin in a changing environment

Hodivala‐Dilke, K. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.06.007 · Cited by 154

Rab11-Family Interacting Protein 2 and Myosin Vb Are Required for CXCR2 Recycling and Receptor-mediated Chemotaxis

Fan, G.-H., Lapierre, L. A., Goldenring, J. R., Sai, J., & Richmond, A. J. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-09-0706 · Cited by 145

Vascular Endothelial Growth Factor-dependent Down-regulation of Flk-1/KDR Involves Cbl-mediated Ubiquitination

Duval, M., Bédard-Goulet, S., Delisle, C., & Gratton, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301410200 · Cited by 132

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Hariharan, S., Gustafson, D. L., Holden, S. N., McConkey, D. J., Davis, D. W., Morrow, M., Basche, M., Gore, L., Zang, C., O’Bryant, C. L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm140 · Cited by 130

Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo

Buerkle, M. A., Pahernik, S. A., Sutter, A., Jonczyk, A., Messmer, K., & Dellian, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600141 · Cited by 130

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Frieß, H., Langrehr, J. M., Oettle, H., Raedle, J., Niedergethmann, M., Dittrich, C., HOSSFELD, D. K., Stöger, H., Neyns, B., Herzog, P., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-285 · Cited by 127

Integrin Inhibitors Reaching the Clinic

Stupp, R., & Rüegg, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8376 · Cited by 122

Superactivation of integrin αvβ3 by low antagonist concentrations

Legler, D. F., Wiedle, G., Ross, F. P., & Imhof, B. A. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.8.1545 · Cited by 112

Alpha v integrin inhibitors and cancer therapy.

Tucker, G. C. (2003) · PubMed · Cited by 108

Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells

Maubant, S., Saint-Dizier, D., Boutillon, M., Perron‐Sierra, F., Casara, P., Hickman, J. A., Tucker, G. C., & Obberghen‐Schilling, E. V. (2006) · Blood · doi:10.1182/blood-2006-05-023580 · Cited by 98

Epidermal Growth Factor Receptor Distribution during Chemotactic Responses

Bailly, M., Wyckoff, J. B., Bouzahzah, B., Hammerman, R., Sylvestre, V. T., Cammer, M., Pestell, R. G., & Segall, J. E. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.11.3873 · Cited by 86

Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents

Chatterjee, S., Matsumura, A., Schradermeier, J., & Gillespie, G. Y. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006444300504 · Cited by 81

Manganese-induced integrin affinity maturation promotes recruitment of αVβ3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src

Dormond, O., Ponsonnet, L., Hasmim, M., Foletti, A., & Rüegg, C. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-11-0728 · Cited by 55

Integrins as biomechanical sensors of the microenvironment

Kechagia, J. Z., Ivaska, J., & Roca-Cusachs, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0134-2 · Cited by 1,311

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets

Jun, J.-I., & Lau, L. F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3599 · Cited by 568

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58832 · Cited by 479